EUVIMEDSkopri EUVIMED
Crossref

Dexmedetomidine Inhibits Ferroptosis by Regulating the SRY‐Box Transcription Factor 9/Divalent Metal Transporter‐1 Axis to Alleviate Cerebral Ischemia/Reperfusion Injury

Zhen Liu, Qionghua Liu, Xuekang Zhang, Gan Li

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70022 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2025. Written by Zhen Liu and 3 co-authors. Institution: Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China. Major MEDLINE topics: Dexmedetomidine, Ferroptosis, Reperfusion Injury, SOX9 Transcription Factor. Cited 4 times so far (Crossref); 49 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Cerebral ischemia/reperfusion injury (IRI) is pathologically associated with ferroptosis. Dexmedetomidine (Dex) exerts neuroprotective activity after cerebral IRI. Our work focused on probing the pharmacologic effect of Dex on ferroptosis during cerebral IRI and the mechanisms involved. Cerebral IRI models were established by oxygen–glucose deprivation/reoxygenation (OGD/R) and middle cerebral artery occlusion (MCAO). 2,3,5‐Triphenyltetrazolium chloride (TTC) staining was utilized to detect cerebral infarct size and mNSS was performed to evaluate neurologic deficits. Brain pathologic changes were analyzed by HE staining. Lipid peroxidation level was detected by C11‐BODIPY staining, and Fe 2+ and MDA levels were measured using the kits. Cell vitality was examined by CCK‐8 assay. Dual‐luciferase reporter and ChIP assays were adopted to determine the interaction between SOX9 and DMT1 promoter. Dex ameliorated ferroptosis and neuronal death induced by MCAO and OGD/R. SOX9 upregulation abolished the inhibitory effect of Dex on OGD/R‐induced ferroptosis and neuronal death in SH‐SY5Y cells. Our further trials showed that SOX9 transcriptionally activated DMT1 expression. As expected, DMT1 overexpression prevented Dex‐induced decrease in ferroptosis and neuronal death in OGD/R‐treated SH‐SY5Y cells. Dex inhibited ferroptosis to exert neuroprotection effects on cerebral IRI by inactivating the SOX9/DMT1 axis.

Subjects

MeSH terms (MEDLINE)

DexmedetomidineFerroptosisReperfusion InjurySOX9 Transcription FactorAnimalsHumansMaleCell Line, TumorBrain IschemiaNeuroprotective AgentsInfarction, Middle Cerebral ArteryMice

Author keywords

DMT1SOX9cerebral ischemia/reperfusion injurydexmedetomidineferroptosis

Substances

DexmedetomidineSOX9 Transcription FactorNeuroprotective AgentsSOX9 protein, human

Authors and institutions

  • Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China.
  • Department of Anesthesiology, Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang, Jiangxi Province, China.

Cite

APA

Liu, Z., Liu, Q., Zhang, X., & Li, G. (2025). Dexmedetomidine Inhibits Ferroptosis by Regulating the SRY‐Box Transcription Factor 9/Divalent Metal Transporter‐1 Axis to Alleviate Cerebral Ischemia/Reperfusion Injury. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70022

Vancouver

Liu Z, Liu Q, Zhang X, Li G. Dexmedetomidine Inhibits Ferroptosis by Regulating the SRY‐Box Transcription Factor 9/Divalent Metal Transporter‐1 Axis to Alleviate Cerebral Ischemia/Reperfusion Injury. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70022

BibTeX
@article{Liu2025,
  author = {Liu, Zhen and Liu, Qionghua and Zhang, Xuekang and Li, Gan},
  title = {Dexmedetomidine Inhibits Ferroptosis by Regulating the SRY‐Box Transcription Factor 9/Divalent Metal Transporter‐1 Axis to Alleviate Cerebral Ischemia/Reperfusion Injury},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70022}
}
Start for free →